Here's Why United Therapeutics (UTHR) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Compared to Estimates, United Therapeutics (UTHR) Q2 Earnings: A Look at Key Metrics
Although the revenue and EPS for United Therapeutics (UTHR) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
United Therapeutics (UTHR) Misses Q2 Earnings Estimates
United Therapeutics (UTHR) came out with quarterly earnings of $6.41 per share, missing the Zacks Consensus Estimate of $6.8 per share. This compares to earnings of $5.85 per share a year ago.
United Therapeutics (UTHR) Crossed Above the 50-Day Moving Average: What That Means for Investors
From a technical perspective, United Therapeutics (UTHR) is looking like an interesting pick, as it just reached a key level of support. UTHR recently overtook the 50-day moving average, and this suggests a short-term bullish trend.
United Therapeutics (UTHR) Earnings Expected to Grow: Should You Buy?
United Therapeutics (UTHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why United Therapeutics (UTHR) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why United Therapeutics (UTHR) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Will United Therapeutics (UTHR) Beat Estimates Again in Its Next Earnings Report?
United Therapeutics (UTHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Why United Therapeutics (UTHR) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
United Therapeutics (UTHR) Soars 3.5%: Is Further Upside Left in the Stock?
United Therapeutics (UTHR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Why Is United Therapeutics (UTHR) Up 9% Since Last Earnings Report?
United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock?
United Therapeutics Corporation (UTHR) Q1 2025 Earnings Call Transcript
United Therapeutics Corporation (NASDAQ:UTHR ) Q1 2025 Earnings Conference Call April 30, 2025 9:00 AM ET Company Participants Dewey Steadman - Head of Investor Relations Martine Rothblatt - Chairperson & Chief Executive Officer Michael Benkowitz - President & Chief Operating Officer Leigh Peterson - Executive Vice President, Product Development and Xenotransplantation James Edgemond - Chief Financial Officer & Treasurer Conference Call Participants Joseph Thome - TD Cowen Jessica Fye - JPMorgan Roanna Ruiz - Leerink Andreas Argyrides - Oppenheimer Roger Song - Jefferies Ash Verma - UBS Operator Good morning and welcome to the United Therapeutics Corporation First Quarter 2025 Corporate Update. My name is Dorwin [ph] and I will be your conference operator today.
